Literature DB >> 23841765

Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B.

R Goldberg, E Smith, S Bell, A Thompson, P V Desmond.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23841765     DOI: 10.1111/imj.12180

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


× No keyword cloud information.
  5 in total

1.  Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System.

Authors:  Akimasa Sanagawa; Yuji Hotta; Tomoya Kataoka; Yasuhiro Maeda; Masahiro Kondo; Yoshihiro Kawade; Yoshihiro Ogawa; Ryohei Nishikawa; Masahiro Tohkin; Kazunori Kimura
Journal:  Cancer Med       Date:  2018-04-16       Impact factor: 4.452

2.  Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib

Authors:  Pınar Ataca Atilla; Merih Yalçıner; Erden Atilla; Ramazan İdilman; Meral Beksaç
Journal:  Turk J Haematol       Date:  2019-08-01       Impact factor: 1.831

3.  Bortezomib induced hepatitis B reactivation.

Authors:  Salwa Hussain; Ruby Jhaj; Samira Ahsan; Muhammad Ahsan; Robert E Bloom; Syed-Mohammed R Jafri
Journal:  Case Rep Med       Date:  2014-05-04

Review 4.  Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma.

Authors:  Yutaka Tsukune; Makoto Sasaki; Norio Komatsu
Journal:  Cancers (Basel)       Date:  2019-11-19       Impact factor: 6.639

5.  Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug: A case report.

Authors:  Xuzhao Zhang; Yun Liang; Xian Li; Weiqin Wang; Jiefeng Tong; Yang Xu
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.